Selected events following insertion of the Progestasert system.
The incidences of selected events were analyzed following insertion of the PROGESTASERT intrauterine progesterone contraceptive system (IPCS) and following its reinsertion after one year of use. Reinsertion did not interrupt the stabilizing or declining trends in incidences of P.I.D., removals for bleeding/pain, removals for other medical reasons, unplanned pregnancies, moderate/severe menstrual cramps and bleeding, and premenstrual/intermenstrual cramps. Comparison of the incidence of P.I.D. in the U.S. population with postinsertion incidence of P.I.D. in IPCS users indicates that the IPCS does not increase the likelihood that a woman will have P.I.D. over the likelihood that she would have it without use of the IPCS. The incidences of expulsions and intermenstrual spotting and bleeding rose temporarily after reinsertion to about half their previous peaks and then diminished markedly within two months, reverting to the levels and favorable patterns of change established during the first year.
D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated / Q000009:adverse effects*; D008599:Menstruation Disturbances / Q000209:etiology; D000292:Pelvic Inflammatory Disease / Q000209:etiology*; D011247:Pregnancy; D011374:Progesterone / Q000009:adverse effects*
D011374:Progesterone